Juno Therapeutics, Inc. (NASDAQ:JUNO) CFO Steve Harr sold 8,750 shares of the company’s stock in a transaction dated Monday, July 3rd. The stock was sold at an average price of $30.00, for a total value of $262,500.00. Following the completion of the sale, the chief financial officer now owns 736,189 shares in the company, valued at approximately $22,085,670. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Steve Harr also recently made the following trade(s):
- On Tuesday, June 27th, Steve Harr sold 8,750 shares of Juno Therapeutics stock. The stock was sold at an average price of $30.00, for a total value of $262,500.00.
Juno Therapeutics, Inc. (NASDAQ:JUNO) opened at 27.31 on Tuesday. The firm’s market cap is $2.84 billion. The firm’s 50 day moving average price is $24.94 and its 200-day moving average price is $22.57. Juno Therapeutics, Inc. has a one year low of $17.52 and a one year high of $35.04.
Juno Therapeutics (NASDAQ:JUNO) last issued its quarterly earnings data on Thursday, May 4th. The biopharmaceutical company reported ($0.71) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.70) by $0.01. Juno Therapeutics had a negative return on equity of 24.57% and a negative net margin of 288.66%. The company had revenue of $19.30 million for the quarter, compared to analyst estimates of $16 million. During the same quarter in the prior year, the firm earned ($0.78) earnings per share. The company’s revenue for the quarter was up 96.9% on a year-over-year basis. Equities analysts predict that Juno Therapeutics, Inc. will post ($2.99) EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “Juno Therapeutics, Inc. (JUNO) CFO Sells $262,500.00 in Stock” was reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are accessing this story on another website, it was stolen and reposted in violation of U.S. & international copyright legislation. The legal version of this story can be viewed at https://www.chaffeybreeze.com/2017/07/18/steve-harr-sells-8750-shares-of-juno-therapeutics-inc-juno-stock-updated.html.
JUNO has been the topic of a number of recent research reports. Vetr upgraded Juno Therapeutics from a “buy” rating to a “strong-buy” rating and set a $25.42 target price on the stock in a research note on Tuesday, March 21st. Wedbush reaffirmed a “neutral” rating and issued a $24.00 price target on shares of Juno Therapeutics in a report on Friday, May 5th. Morgan Stanley reduced their price target on Juno Therapeutics from $27.00 to $26.00 and set an “equal weight” rating for the company in a report on Monday, May 8th. Citigroup Inc. reduced their price target on Juno Therapeutics from $34.00 to $30.00 and set a “buy” rating for the company in a report on Tuesday, April 4th. Finally, FBR & Co reaffirmed a “hold” rating on shares of Juno Therapeutics in a report on Thursday, May 18th. One research analyst has rated the stock with a sell rating, six have issued a hold rating and nine have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $30.81.
Several hedge funds and other institutional investors have recently modified their holdings of JUNO. Creative Planning increased its position in shares of Juno Therapeutics by 5.9% in the second quarter. Creative Planning now owns 50,827 shares of the biopharmaceutical company’s stock valued at $1,519,000 after buying an additional 2,811 shares during the period. Point72 Asset Management L.P. acquired a new position in shares of Juno Therapeutics during the first quarter valued at $1,951,000. Credit Suisse AG increased its position in shares of Juno Therapeutics by 58.5% in the first quarter. Credit Suisse AG now owns 305,593 shares of the biopharmaceutical company’s stock valued at $6,781,000 after buying an additional 112,787 shares during the period. Iguana Healthcare Management LLC acquired a new position in shares of Juno Therapeutics during the first quarter valued at $2,219,000. Finally, Peconic Partners LLC acquired a new position in shares of Juno Therapeutics during the first quarter valued at $3,329,000. Hedge funds and other institutional investors own 64.51% of the company’s stock.
Juno Therapeutics Company Profile
Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.
Receive News & Ratings for Juno Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.